Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-LAG-3 and Anti-TIGIT in Relapsed Refractory Multiple Myeloma
NCT04150965Phase 2Terminated
- Start
- Jul 2020
- Primary completion
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of relatlimab, BMS-986207 in multiple myeloma (MM). Started Jul 2020; status: terminated.
02
Drugs
relatlimabBMS-986207
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04150965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04150965.